#Israel #CollPlant #rhCollagen #Rehovot #regenerative medicine

CollPlant Biotechnologies Unveils Their Redesigned Corporate Website

On March 18, 2026, CollPlant Biotechnologies (Nasdaq: CLGN), a pioneering company in regenerative and aesthetic medicine, announced the launch of its newly redesigned corporate website, which can be accessed at www.collplant.com. This updated platform is crafted to provide an expansive view of the innovative technologies and products stemming from CollPlant's proprietary plant-derived recombinant human collagen (rhCollagen).

The revamped website aims to improve accessibility and transparency for investors, partners, and other stakeholders by offering a comprehensive overview of various key aspects of the company's operations. The redesigned site focuses on several core areas, including:

1. Proprietary rhCollagen Technology: Detailed information regarding CollPlant's unique technology and its manufacturing processes, which are central to their product offerings.
2. Product Development Pipeline: An overview of the current pipeline of product innovations, which includes regenerative breast implants, dermal fillers, and bioinks.
3. Strategic Partnerships: Insights into current collaborations and partnerships, which are vital for the company's growth and innovation in the regenerative medicine space.
4. Investor Relations Resources: The site provides essential resources such as SEC filings, financial reports, and corporate presentations in order to foster investor trust and engagement.
5. Corporate Governance Materials: Transparency in corporate governance with detailed leadership information and structures.

Yehiel Tal, Chief Executive Officer of CollPlant, expressed excitement about their new digital platform, stating, "We are pleased to introduce our redesigned corporate website, which reflects CollPlant's continued advancement as a regenerative medicine and aesthetics company. The new platform provides clear and comprehensive information regarding our rhCollagen technology, product pipeline, and strategic direction. We believe the enhanced website will improve engagement with business partners and investors as we continue to execute on our development and commercialization objectives."

The website serves as a central hub for information related to CollPlant's technological advancements, clinical and preclinical programs, and significant corporate updates. This level of transparency is crucial for attracting investors and partners who are vital for the company’s ongoing innovation and success in the market.

Furthermore, CollPlant focuses on the application of its rhCollagen products across diverse fields, including tissue repair and aesthetics. The company is actively engaged in the pioneering domain of 3D bioprinting, emphasizing the potential for creating tissues and organs tailored to medical needs. The solutions provided by CollPlant are aimed at elevating the standards and possibilities in regenerative and aesthetic medicine, representing a shift towards more natural and effective methodologies in these fields.

As part of its commitment to innovation, CollPlant entered into a significant global commercialization agreement with Allergan, an AbbVie company recognized as a leader in the dermal filler market. This partnership highlights CollPlant's strategic direction and underscores its dedication to advancing its product offerings.

In closing, the launch of the redesigned corporate website marks a significant stride for CollPlant Biotechnologies, demonstrating a commitment to transparency and offering key stakeholders access to vital information that can aid in understanding the company's mission and future direction. For further inquiries, CollPlant has established direct communication channels via their website or through contact at [email protected]

To explore more about CollPlant’s innovative contributions to regenerative medicine and aesthetics, visit www.CollPlant.com.